Skip to main content

Table 1 Patient characteristics of MSC group and non-MSC group

From: Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study

  MSC group (n = 47) Non-MSC group (n = 60) p value
No. (%) No. (%)
Age (year)
Mean ± SD (range) 6.19 ± 3.04 (1.10–15) 6.54 ± 2.94 (1.10–15) 0.608
 ≤ 7 33 (70.21) 42 (70.00) 0.981
 > 7 14 (29.79) 18 (30.00)  
Sex 0.778
 Male 31 (65.96) 38 (63.33)  
 Female 16 (34.04) 22 (36.67)  
Pneumonia 0.306
 Non-severe 31 (65.96) 45 (75)  
 Severe 16 (34.04) 15 (25)  
HSC sourcea 0.454
 Peripheral blood 41 (87.23) 55 (91.67)  
 Umbilical cord blood 6 (12.77) 5 (8.33)  
HSC donor typeb 0.800
 Matched 27 (57.45) 33(55.00)  
 Mismatched 20 (42.55) 27 (45.00)  
Primary diseases 0.176
 Thalassemia 36 (76.60) 52 (86.67)  
 Others 11 (23.40) 8(13.33)  
Interval daysc
 ≥ 100 20 (42.55) 19 (31.67) 0.246
 < 100 27 (57.45) 41 (68.33)  
Virus serostatus 0.725
 Negative 29 (61.70) 39 (65.00)  
 Positive 18 (38.30) 21 (35.00)  
Virus (serostatus + BAL)d
 Negative 23 (48.94) 33 (55.00) 0.533
 Positive 24 (51.06) 27 (45.00)  
Bacteria/fungi 0.454
 Negative 41 (87.23) 55 (91.67)  
 Positive 6 (12.77) 5 (8.33)  
MSC infusion times
 Mean ± SD (Median, range) 4.04 ± 2.11 (4, 1–11)   
  1. a,bHSC: hematopoietic stem cell
  2. cDays between pneumonia onset and hematopoietic stem cell transplantation
  3. dBAL: bronchoalveolar lavage fluid